Human infection by avian influenza A H5N1

Hong Kong Medical Journal

Volumn 11, Issue 3, 2005, Pages 189-199

  Yuen, K Y ^a   Wong, S S Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hemagglutinins; Humans; Influenza A virus, avian; Influenza A virus, human

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMAGGLUTININ; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; INTERFERON; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MATRIX PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOKINE; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; OSELTAMIVIR; OXYGEN; PROTEIN; PROTEIN M2; RECEPTOR; RECOMBINANT ANTIGEN; RIMANTADINE; RNA POLYMERASE; SIALIC ACID; SIALIDASE; SIALIDASE INHIBITOR; SMALL INTERFERING RNA; SODIUM; SODIUM CHANNEL; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN; VIRUS RNA; ZANAMIVIR;

ANTIBODY TITER; ANTIGENICITY; ARTIFICIAL VENTILATION; ASSISTED VENTILATION; AVIAN INFLUENZA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; IMMUNOFLUORESCENCE TEST; INFECTION CONTROL; INFLUENZA VIRUS A; INTENSIVE CARE; LUNG LAVAGE; NONHUMAN; PATIENT CARE; PHYLOGENY; PNEUMONIA; PNEUMOTHORAX; POULTRY; PROGNOSIS; PUBLIC HEALTH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; REYE SYNDROME; RISK FACTOR; RNA INTERFERENCE; SERODIAGNOSIS; THORAX RADIOGRAPHY; THROAT CULTURE; VACCINATION; VIRUS CULTURE; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION; VIRUS VIRULENCE; WESTERN BLOTTING;

CROSS INFECTION; HONG KONG; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; PUBLIC HEALTH; TERMINOLOGY; VIRULENCE;

EID: 20444436368     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Fouchier RA, Munster V, Wallensten A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 2005;79:2814-22.
2. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2005-2006 influenza season. Wkly Epidemiol Rec 2005;80:71-5.
3. Tran TH, Nguyen TL, Nguyen TD, et al; World Health Organization International Avian Influenza Investigative Team. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350:1179-88.
4. Krug RM. The potential use of influenza virus as an agent for bioterrorism. Antiviral Res 2003;57:147-50.
5. Potter CW. A history of influenza. J Appl Microbiol 2001;91:572-9.
6. Klimov A, Simonsen L, Fukuda K, Cox N. Surveillance and impact of influenza in the United States. Vaccine 1999;17 (Suppl 1):42S-46S.
7. Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA 2004;101:1356-61.
8. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004;363:587-93.
9. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet 1999;354:916-7.
10. Lin YP, Shaw M, Gregory V, et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA 2000; 97:9654-8.
11. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-71.
12. Chan PK. Outbreak of avian influenza A(HSN1) virus infection in Hong Kong in 1997. Clin Infect Dis 2002;34(Suppl 2):58S-64S.
13. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004;363:617-9.
14. Update on H5N1 in humans, 18 April 2005. World Health Organization website: http://www.wpro.who.int/media_centre/press_releases/pr_20050418.htm. Accessed on 24 April 05.
15. Guan Y, Peiris JS, Lipatov AS, et al. Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci USA 2002;99:8950-5.
16. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004;430:209-13.
17. Keawcharoen J, Oraveerakul K, Kuiken T, et al. Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis 2004;10:2189-91.
18. Govorkova EA, Rehg JE, Krauss S, et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005;79:2191-8.
19. Kuiken T, Rimmelzwaan GF, Van Amerongen G, Osterhaus AD. Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol 2003;40:304-10.
20. Kuiken T, Rimmelzwaan G, van Riel D, et al. Avian H5N1 influenza in cats. Science 2004;306:241.
21. Liem NT, Lim W; World Health Organization International Avian Influenza Investigation Team, Vietnam. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis 2005;11:210-5.
22. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005;352:333-40.
23. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 1999;180:505-8.
24. Bridges CB, Lim W, Hu-Primmer J, et al. Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis 2002;185:1005-10.
25. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci USA 2004;101:6146-51.
26. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci USA 2004;101:4620-4.
27. Recommendations on the prevention, control and eradication of highly pathogenic avian influenza (HPAI) in Asia, September 2004. Food and Agriculture Organization of the United Nations website: http://www.fao.org/ag/againfo/ subjects/en/health/diseases-cards/avian_fao.html. Accessed on 24 April 2005.
28. Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev 2001;14:129-49.
29. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279:393-6.
30. Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y. PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology 2004;320:258-66.
31. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 2002;8:950-4.
32. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002;360:1831-7.
33. Kunzelmann K, Beesley AH, King NJ, Karupiah G, Young JA, Cook DI. Influenza virus inhibits amiloride-sensitive Na+ channels in respiratory epithelia. Proc Natl Acad Sci USA 2000;97:10282-7.
34. Chen XJ, Seth S, Yue G, et al. Influenza virus inhibits ENaC and lung fluid clearance. Am J Physiol Lung Cell Mol Physiol 2004;287:L366-73.
35. Katz JM, Lim W, Bridges CB, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 1999;180:1763-70.
36. Buxton Bridges C, Katz JM, Seto WH, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 2000;181:344-8.
37. Apisarnthanarak A, Kitphati R, Thongphubeth K, et al. Atypical avian influenza (H5N1). Emerg Infect Dis 2004;10:1321-4.
38. de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005;352:686-91.
39. Updated situation of human avian influenza infection in Vietnam. Hong Kong: Centre for Health Protection; 23 April 2005.
40. Centers for Disease Control and Prevention (CDC). Cases of influenza A (H5N1)-Thailand, 2004. MMWR Morb Mortal Wkly Rep 2004;53:100-3.
41. To KF, Chan PK, Chan KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001;63:242-6.
42. Iwasaki T, Itamura S, Nishimura H, et al. Productive infection in the murine central nervous system with avian influenza virus A (H5N1) after intranasal inoculation. Acta Neuropathol (Berl) 2004;108:485-92.
43. WHO manual on animal influenza diagnosis and surveillance. 2002. World Health Organization website: http://www.who.int/csr/resources/publications/ influenza/WHO_CDS_CSR_NCS_2002_5/en/. Accessed on 24 Apr 05.
44. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-43.
45. Peters LJ, Wiener GJ, Gilliam J, Van Noord G, Geisinger KR, Roach ES. Reye's syndrome in adults. A case report and review of the literature. Arch Intern Med 1986;146:2401-3.
46. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001;45:2723-32.
47. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55(Suppl 1):i5S-i21S.
48. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845-50.
49. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:1016-24.
50. McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs 2001;61:263-83.
51. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000;343:1282-9.
52. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235-40.
53. Influenza A (H5N1): WHO Interim Infection Control Guidelines for Health Care Facilities. 2004. World Health Organization website: http://www.who.int/ csr/disease/avian_influenza/guidelines/infectioncontroll/en/.
54. Avian influenza: assessing the pandemic threat. 2005. World Health Organization website: http://www.who.int/csr/disease/influenza/WHO_CDS_2005_29/ en/.
55. Dave RS, Pomerantz RJ. RNA interference: on the road to an alternate therapeutic strategy! Rev Med Virol 2003;13:373-85.
56. Ge Q, Eisen HN, Chen J. Use of siRNAs to prevent and treat influenza virus infection. Virus Res 2004;102:37-42.
57. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA 2004;101:8682-6.
58. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004;101:8676-81.
59. Goldmann DA. Epidemiology and prevention of pediatric viral respiratory infections in health-care institutions. Emerg Infect Dis 2001;7:249-53.
60. Goldmann DA. Transmission of viral respiratory infections in the home. Pediatr Infect Dis J 2000;19(10 Suppl):97S-102S.
61. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003;37:1094-101.
62. Interim recommendations for infection control in health-care facilities caring for patients with known or suspected avian influenza. Centers for Disease Control and Prevention website: http://www.cdc.gov/flu/avian/professional/ infect-control.htm. Accessed on 24 Apr 05.
63. Taylor HR, Turner AJ. A case report of fowl plague keratoconjunctivitis. Br J Ophthalmol 1977;61:86-8.
64. Poon LL, Leung CS, Chan KH, et al. Detection of human influenza A viruses by loop-mediated isothermal amplification. J Clin Microbiol 2005;43:427-30.